Consun Pharmaceutical Group (SEHK:1681) Valuation Check After Expanded HK$300 Million Share Buyback Plan

Simply Wall St.

01/31

AdvertisementConsun Pharmaceutical Group expands buyback plan Consun Pharmaceutical Group (SEHK:1681) has expanded its existing share repurchase plan, adding HK$100 million to the programme to allow ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2607075121"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607075121\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607075121?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-01-31 10:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607075121","market":"us","top_or_hot":-1,"title":"Consun Pharmaceutical Group (SEHK:1681) Valuation Check After Expanded HK$300 Million Share Buyback Plan","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementConsun Pharmaceutical Group expands buyback plan Consun Pharmaceutical Group (SEHK:1681) has expanded its existing share repurchase plan, adding HK$100 million to the programme to allow ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-valuation-check-after-e\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Consun Pharmaceutical Group (SEHK:1681) Valuation Check After Expanded HK$300 Million Share Buyback Plan</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nConsun Pharmaceutical Group (SEHK:1681) Valuation Check After Expanded HK$300 Million Share Buyback Plan\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-01-31 10:25</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>AdvertisementConsun Pharmaceutical Group expands buyback plan Consun Pharmaceutical Group (SEHK:1681) has expanded its existing share repurchase plan, adding HK$100 million to the programme to allow ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-valuation-check-after-e\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-valuation-check-after-e\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-valuation-check-after-e","article_id":"2607075121","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1681/consun-pharmaceutical-group-shares/news/consun-pharmaceutical-group-sehk1681-valuation-check-after-e","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607075121","pubTimestamp":1769826359,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Consun Pharmaceutical Group expands buyback plan\nConsun Pharmaceutical Group (SEHK:1681) has expanded its existing share repurchase plan, adding HK$100 million to the programme to allow for up to HK$300 million in potential buybacks funded from existing cash resources.\nSee our latest analysis for Consun Pharmaceutical Group.\nThe increased buyback plan comes after a strong run in the shares, with a 15.54% 1 month share price return and a 20.23% 3 month share price return helping support a very...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1606":"中医药概念","01681":"康臣药业","BK1191":"制药"},"translate_title":"康臣药业集团(SEHK：1681)扩大3亿港元股份回购计划后估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"01681":0.9},"content_text":"AdvertisementConsun Pharmaceutical Group expands buyback plan Consun Pharmaceutical Group (SEHK:1681) has expanded its existing share repurchase plan, adding HK$100 million to the programme to allow for up to HK$300 million in potential buybacks funded from existing cash resources. See our latest analysis for Consun Pharmaceutical Group. The increased buyback plan comes after a strong run in the shares, with a 15.54% 1 month share price return and a 20.23% 3 month share price return helping support a very large 1 year total shareholder return. This suggests that positive momentum has been building. If this kind of move in healthcare names has your attention, it could be a good moment to see what else is available through healthcare stocks. With management signalling confidence through a larger buyback and an intrinsic value estimate that sits above the current HK$18.07 share price, you have to ask: is Consun still undervalued, or is the market already pricing in future growth? Preferred P/E of 13.4x: Is it justified? On a P/E of 13.4x, Consun Pharmaceutical Group screens as slightly more expensive than the wider Hong Kong pharmaceuticals industry, but still cheaper than its closer peer group and below an estimated fair P/E level. The P/E ratio compares the HK$18.07 share price to the company’s earnings per share and is a common shorthand for how much investors are paying for each unit of current profit. For a healthcare name with Chinese medicine and contrast medium products, earnings quality and growth expectations often matter as much as the raw multiple. Here, the picture is mixed. Consun is described as good value relative to its peer average P/E of 28.8x and to an estimated fair P/E of 17.3x. However, it is labelled expensive versus the broader Hong Kong pharmaceuticals industry average of 13.2x. That suggests the market is assigning a premium over the sector as a whole, but still pricing the shares below where a fair value model and closer peers might justify if earnings and returns stay on track. Compared with the industry’s 13.2x, the 13.4x P/E is only slightly higher, which points to a tight valuation gap. Against peers on 28.8x and a fair P/E of 17.3x, though, the current multiple looks restrained and offers room the market could move towards if sentiment or fundamentals remain supportive. Explore the SWS fair ratio for Consun Pharmaceutical Group Result: Price-to-Earnings of 13.4x (UNDERVALUED) However, you still need to watch for setbacks in key kidney and contrast medium products, and any regulatory changes that affect Chinese medicine approvals or pricing. Find out about the key risks to this Consun Pharmaceutical Group narrative. Another view: DCF points to deeper value While the 13.4x P/E hints at value, our DCF model goes further, suggesting HK$18.07 is around 30.6% below an estimated fair value of HK$26.05. If cash flows are closer to this view than the current multiple suggests, is the market underestimating the story? Look into how the SWS DCF model arrives at its fair value. 1681 Discounted Cash Flow as at Jan 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Consun Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 868 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own Consun Pharmaceutical Group Narrative If you look at the numbers and reach a different conclusion, or simply prefer to work from your own framework, you can build a personalised Consun view in just a few minutes with Do it your way. A great starting point for your Consun Pharmaceutical Group research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? If you are weighing what to do next, do not stop at a single stock. Broaden your watchlist with a few focused idea sets that match your style.  Scan for potential bargains that the market may be overlooking by checking out these 868 undervalued stocks based on cash flows, built purely around cash flow value. Target fast evolving themes in technology by reviewing these 25 AI penny stocks that sit at the intersection of computing power and real world applications. Hunt for income ideas that still offer equity upside through these 14 dividend stocks with yields > 3%, focused on companies with yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}